169 related articles for article (PubMed ID: 29731877)
21. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
[No Abstract] [Full Text] [Related]
22. Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report.
Sheel A; Bae J; Asada A; Otterson GA; Baliga RR; Koenig KL
Cardiooncology; 2023 Jan; 9(1):4. PubMed ID: 36653885
[TBL] [Abstract][Full Text] [Related]
23. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories.
Loghavi S; Sui D; Wei P; Garcia-Manero G; Pierce S; Routbort MJ; Jabbour EJ; Pemmaraju N; Kanagal-Shamanna R; Gur HD; Hu S; Zuo Z; Medeiros LJ; Kantarjian HM; Khoury JD
Blood Adv; 2018 Aug; 2(15):1807-1816. PubMed ID: 30054307
[TBL] [Abstract][Full Text] [Related]
24. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
25. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.
Parikh SA; Tefferi A
Am J Hematol; 2012 Jun; 87(6):610-9. PubMed ID: 22615103
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy, Prognosis and Safety of Decitabine Combined with Low-Dose Cytarabine in the Treatment of Elderly Patients with Relapsed/Refractory Acute Myeloid Leukemia].
Chen D; Lu Y; Yan RZ; Ye PP; Zhang YS; Ma JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):390-395. PubMed ID: 30998143
[TBL] [Abstract][Full Text] [Related]
27. Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.
Huang J; Zhao H; Hong M; Zhu H; Zhu Y; Lian Y; Li S; Li J; Qian S
BMC Cancer; 2018 Dec; 18(1):1269. PubMed ID: 30567513
[TBL] [Abstract][Full Text] [Related]
28. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
Padron E; Steensma DP
Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
[TBL] [Abstract][Full Text] [Related]
29. Improving the accuracy of prognostication in chronic myelomonocytic leukemia.
Kaivers J; Schuler E; Hildebrandt B; Betz B; Rautenberg C; Haas R; Kobbe G; Gattermann N; Germing U
Expert Rev Anticancer Ther; 2020 Aug; 20(8):703-714. PubMed ID: 32700646
[TBL] [Abstract][Full Text] [Related]
30. Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis.
Ma YY; Zhao M; Liu Y; Zhao DF; Wang LX; Chen XP; Li L
Hematology; 2019 Dec; 24(1):507-515. PubMed ID: 31242832
[No Abstract] [Full Text] [Related]
31. Decitabine before Low-Dose Cytarabine-Based Chemotherapy Combined with Human Leukocyte Antigen-Mismatched Stem Cell Microtransplantation Improved Outcomes in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Zhu Y; Zhao H; Zhang X; Wu Y; Xie Y; Li Y; Lian Y; Huang J; Li J; Chen Y; Qian S
Biol Blood Marrow Transplant; 2017 May; 23(5):830-835. PubMed ID: 28189902
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
Weihrauch MR; Staib P; Seiberlich B; Hoffmann M; Diehl V; Tesch H
Leuk Lymphoma; 2004 Apr; 45(4):699-704. PubMed ID: 15160942
[TBL] [Abstract][Full Text] [Related]
33. Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia.
Hunter AM; Zhang L; Padron E
Curr Treat Options Oncol; 2018 Oct; 19(12):67. PubMed ID: 30367269
[TBL] [Abstract][Full Text] [Related]
34. Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome.
Stomper J; Ihorst G; Suciu S; Sander PN; Becker H; Wijermans PW; Plass C; Weichenhan D; Bissé E; Claus R; Lübbert M
Haematologica; 2019 Jan; 104(1):59-69. PubMed ID: 30171030
[TBL] [Abstract][Full Text] [Related]
35. Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype.
Huh YO; Tang G; Talwalkar SS; Khoury JD; Ohanian M; Bueso-Ramos CE; Abruzzo LV
Cancer Genet; 2016; 209(7-8):313-20. PubMed ID: 27318442
[TBL] [Abstract][Full Text] [Related]
36. The role of decitabine for the treatment of acute myeloid leukemia.
Ganetsky A
Ann Pharmacother; 2012 Nov; 46(11):1511-7. PubMed ID: 23115225
[TBL] [Abstract][Full Text] [Related]
37. Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML.
Calvo X; Nomdedeu M; Santacruz R; Martínez N; Costa D; Pereira A; Estrada N; Xicoy B; Esteve J; Nomdedeu B
Leuk Res; 2015 Jul; ():. PubMed ID: 26354683
[TBL] [Abstract][Full Text] [Related]
38. Acute myelomonocytic leukemia and T-lymphoblastic lymphoma as simultaneous bilineage hematologic malignancy treated with decitabine: A case report.
Jeon SY; Lee NR; Cha S; Yhim HY; Kwak JY; Jang KY; Kim N; Cho YG; Lee CH
World J Clin Cases; 2023 Jul; 11(21):5129-5135. PubMed ID: 37583856
[TBL] [Abstract][Full Text] [Related]
39. Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Choi EJ; Lee JH; Park HS; Lee JH; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):290-299.e3. PubMed ID: 30879987
[TBL] [Abstract][Full Text] [Related]
40. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]